@article {Ritchiee250233, author = {Duncan Taylor Ritchie and James Dixon}, title = {SGLT-2 inhibitor associated euglycaemic diabetic ketoacidosis in an orthopaedic trauma patient}, volume = {15}, number = {9}, elocation-id = {e250233}, year = {2022}, doi = {10.1136/bcr-2022-250233}, publisher = {BMJ Specialist Journals}, abstract = {Euglycaemic diabetic ketoacidosis is a serious but rare adverse effect of treatment with sodium-glucose cotransporter-2 (SGLT-2) inhibitors. A man in his 60s with type 2 diabetes mellitus underwent total hip replacement for an intracapsular neck of femur fracture. His SGLT-2 inhibitor was continued perioperatively and blood glucose levels were normal throughout the admission. A diagnosis of severe euglycaemic diabetic ketoacidosis was made in the operating theatre which required treatment in a critical care unit. This resulted in increased morbidity due to decreased postoperative mobilisation and a new requirement for subcutaneous insulin. This case highlights the need for withholding SGLT-2 inhibitors in patients admitted for emergency surgery and a need for regular ketone monitoring in these patients, even in the context of normoglycaemia.}, URL = {https://casereports.bmj.com/content/15/9/e250233}, eprint = {https://casereports.bmj.com/content/15/9/e250233.full.pdf}, journal = {BMJ Case Reports CP} }